Catalyst
Monitor the outcomes of Part 1 for safety and PK data, which will inform dosing in Part 2, as well as any regulatory implications that arise from the study results.
Date
July 2, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.